Eligible patients
Forty‐one (60%) trial‐eligible patients received durvalumab following approval and availability in our jurisdiction. Median PFS in eligible patients who did not receive durvalumab was 8.8 months compared to 26.8 months in eligible patients who received durvalumab (HR 0.63, 95% CI 0.36–1.10, 